Abstract
Background: In patients with diabetes mellitus (DM) there is a clear association between blood pressure (BP) levels and macrovascular and microvascular complications. However, the BP targets that need to be achieved for optimal outcomes remain controversial.
Methods: The purpose of this narrative review is to discuss BP targets and management in patients with DM. The subject of elevated heart rate, which has been associated with mortality in many populations, and which is observed in some patients with DM will also be addressed.
Results: Most guidelines recommend a target BP in patients with DM of <140/90 mmHg. Most consistently recommended first-line pharmacotherapy for the treatment of hypertension in non-black patients with DM is an angiotensin converting enzyme (ACE) inhibitor or an angiotensin receptor blocker (ARB) while for black patients a calcium channel blocker or a thiazide diuretic. Newer antidiabetic drugs, such as the glucagon-like peptide-1 (GLP-1) receptor agonists and the sodium glucose co-transporter-2 (SGLT2) inhibitors lower not only blood glucose but also BP levels. The SGLT2 inhibitor-associated decrease in BP is not accompanied by an increase in heart rate, which is observed however with GLP-1 receptor agonists.
Conclusion: The most widely accepted BP target for patients with DM among guidelines is <140/90 mmHg and the most widely accepted pharmacotherapy to achieve these goals are ACE inhibitors and ARBs. Newer antidiabetic medications have been shown to also lower BP and decrease cardiovascular events, thus representing a promising new therapeutic option for patients with DM and hypertension.
Keywords: Diabetes, DPP-4 inhibitor, GLP-1 receptor agonist, guidelines, heart rate, hypertension, SGLT-2 inhibitor.
Current Pharmaceutical Design
Title:Management of Blood Pressure and Heart Rate in Patients with Diabetes Mellitus
Volume: 23 Issue: 31
Author(s): Ioanna Gouni-Berthold*, Ruth Hanssen, Lisa Ravarani and Heiner K. Berthold
Affiliation:
- Polyclinic for Endocrinology, Diabetes and Preventive Medicine (PEDP), University of Cologne, Kerpener Str. 62, 50937 Cologne,Germany
Keywords: Diabetes, DPP-4 inhibitor, GLP-1 receptor agonist, guidelines, heart rate, hypertension, SGLT-2 inhibitor.
Abstract: Background: In patients with diabetes mellitus (DM) there is a clear association between blood pressure (BP) levels and macrovascular and microvascular complications. However, the BP targets that need to be achieved for optimal outcomes remain controversial.
Methods: The purpose of this narrative review is to discuss BP targets and management in patients with DM. The subject of elevated heart rate, which has been associated with mortality in many populations, and which is observed in some patients with DM will also be addressed.
Results: Most guidelines recommend a target BP in patients with DM of <140/90 mmHg. Most consistently recommended first-line pharmacotherapy for the treatment of hypertension in non-black patients with DM is an angiotensin converting enzyme (ACE) inhibitor or an angiotensin receptor blocker (ARB) while for black patients a calcium channel blocker or a thiazide diuretic. Newer antidiabetic drugs, such as the glucagon-like peptide-1 (GLP-1) receptor agonists and the sodium glucose co-transporter-2 (SGLT2) inhibitors lower not only blood glucose but also BP levels. The SGLT2 inhibitor-associated decrease in BP is not accompanied by an increase in heart rate, which is observed however with GLP-1 receptor agonists.
Conclusion: The most widely accepted BP target for patients with DM among guidelines is <140/90 mmHg and the most widely accepted pharmacotherapy to achieve these goals are ACE inhibitors and ARBs. Newer antidiabetic medications have been shown to also lower BP and decrease cardiovascular events, thus representing a promising new therapeutic option for patients with DM and hypertension.
Export Options
About this article
Cite this article as:
Gouni-Berthold Ioanna *, Hanssen Ruth, Ravarani Lisa and Berthold K. Heiner , Management of Blood Pressure and Heart Rate in Patients with Diabetes Mellitus, Current Pharmaceutical Design 2017; 23 (31) . https://dx.doi.org/10.2174/1381612823666170609084436
DOI https://dx.doi.org/10.2174/1381612823666170609084436 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The State of the Problem of Achieving Extremely Low LDL Levels
Current Pharmaceutical Design Meal Replacement Beverage Twice a Day in Overweight and Obese Adults (MDRC2012-001)
Current Nutrition & Food Science Greener Liquid Chromatography for Simultaneous Determination of Rosiglitazone and Glimepiride in Rat Sera and its Application to a Pharmacokinetic Study
Current Analytical Chemistry Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk
Current Vascular Pharmacology Antioxidant Activity of Plant Phenols: Chemical Mechanisms and Biological Significance
Current Organic Chemistry Heme Oxygenase-1 as a Target for the Design of Gene and Pharmaceutical Therapies for Autoimmune Diseases
Current Gene Therapy Postprandial Hypotension - Novel Insights into Pathophysiology and Therapeutic Implications
Current Vascular Pharmacology Capsaicin-Sensitive Nociceptive Innervation of the Dura Mater: Implications for the Pathomechanism of Headache
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry An Insight on the Leading HIV Entry Inhibitors
Recent Patents on Anti-Infective Drug Discovery Structure-Function Relationships of PEDF
Current Molecular Medicine Intravitreal Inserts of Steroids to Treat Diabetic Macular Edema
Current Diabetes Reviews Nitric Oxide-Derived Oxidants with a Focus on Peroxynitrite: Molecular Targets,Cellular Responses and Therapeutic Implications
Current Pharmaceutical Design Metabolic Syndrome and Diabetic Atherothrombosis: Implications in Vascular Complications
Current Molecular Medicine Synthesis, Characterization and <i>in vivo</i> Evaluation of PEGylated PPI Dendrimer for Safe and Prolonged Delivery of Insulin
Drug Delivery Letters Glucagon Like Peptides-1 Modulators as Newer Target for Diabetes
Current Drug Targets Association of PPARG Gene Polymorphisms Pro12Ala with Type 2 Diabetes Mellitus: A Meta-analysis
Current Diabetes Reviews Stable Angina Pectoris: Current Medical Treatment
Current Pharmaceutical Design The No-Reflow Phenomenon in the Coronary Circulation
Cardiovascular & Hematological Agents in Medicinal Chemistry Role of PI3K/AKT, cPLA2 and ERK1/2 Signaling Pathways in Insulin Regulation of Vascular Smooth Muscle Cells Proliferation
Cardiovascular & Hematological Disorders-Drug Targets Enhancement of Skin Permeation of Glibenclamide from Ethyl Cellulose- Polyvinyl Pyrollidone based Transdermal Patches using Olive Oil and Mustard oil as Penetration Enhancer: In Vitro, Ex-Vivo and In Vivo Evaluation
Drug Delivery Letters